Back to results
US 6,190,884 B1Granted
Connective tissue growth factor
AssigneeUniversity of South Florida
InventorsGary R. Grotendorst, Douglas M. Bradham, Jr.
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeUniversity of South Florida
InventorsGary R. Grotendorst, Douglas M. Bradham, Jr.
Estimating the term…
The invention relates to a method of producing connective tissue growth factor (CTGF). A method of the invention can be performed, for example, by transforming a host cell with a polynucleotide encoding a CTGF polypeptide having an amino acid sequence of SEQ ID NO: 2 or an active fragment thereof; and growing the host cells under conditions suitable for expressing the polynucleotide in the host cell. In an embodiment, the method further involves isolating the CTGF polypeptide or the active fragment. The invention also relates to a method for producing a vector containing a polynucleotide encoding a CTGF polypeptide or an active fragment thereof by inserting a polynucleotide encoding a CTGF polypeptide having an amino acid sequence of SEQ ID NO: 2 or a variant thereof into the vector. The vector can be an expression vector, for example, a plasmid expression vector or a viral expression vector. In an embodiment, the polynucleotide has a nucleotide sequence of SEQ ID NO: 1 or a variant thereof.
A method of producing connective tissue growth factor (CTGF) comprising:
A method for producing a vector containing a polynucleotide encoding a connective tissue growth factor (CTGF) polypeptide comprising inserting a polynucleotide encoding a CTGF polypeptide comprising the amino acid sequence of SEQ ID NO:
Dependencies are inferred from the claim text.
Drawings are temporarily unavailable. Open the PDF at USPTO
From the US filing history. Foreign family members aren’t listed.
Against material from animals or humans: against growth factors ; against growth regulators
From animals; from humans: growth factors; Growth regulators
Medicinal preparations containing peptides
Peptide or protein sequence: growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related…
Term ended 30 Aug 2011 (estimated)
USPTO file history isn’t available for this patent, so only indexed dates are shown.
1. Field of the Invention
This invention relates generally to the field of growth factors and specifically to Connective Tissue Growth Factor (CTGF) and the gene encoding this factor.
2. Related Art
Cells
Human umbilical vein endothelial (HUVE) cells were isolated from fresh human umbilical cords by collagenase perfusion (Jaffe, et al., Human Pathol., 18:234, 1987) and maintained in medium 199 with 20% FCS, 0.68 mM L-glutamine, 20 μg/ml Gentamicin, 90 μg/ml porcine heparin (Sigma, St. Louis, Mo.), and 50 μg/ml Endothelial Cell Growth Supplement (Sigma). Cells used for media collection were third passage cells. Cells were identified as endothelial cells by their non-overlapping cobblestone morphology and by positive staining for Factor-VIII related antigen. NRK cells were obtained from American Type Culture, NIH/3T3 cells were a gift from S. Aaronson (NCI, Bethesda, Md.), and both cell lines were maintained in DMEM, 10% FCS, 20 μg/ml Gentamicin. Fetal bovine aortic smooth muscle cells were obtained from tissue explants as previously described (Grotendorst, et al., Proc. Natl. Acad. Sci. USA, 78:3669, 1981) and maintained in DMEM, 10% FCS, 20 μg/ml Gentamicin, and used in assays at second or third passage.
Growth Factors and Antibodies